Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: A case report and review of literature.
Despite improvements in first-line treatment of T-cell acute lymphoblastic leukemia (T-ALL), the outcome of relapsed T-ALL remains dismal with less than 7% achieving a long-term survival. Thus, there is an unmet need for new treatment strategies to improve outcomes in this setting. Suppression of apoptosis is one of the hallmarks of anticancer drug resistance. Hence, over the past few years, antiapoptotic proteins have become an attractive target for therapeutic intervention in several hematologic malignancies. Venetoclax (ABT-199) is a novel, orally bioavailable small-molecule inhibitor of B-cell lymphoma 2 (BCL-2), a key regulator of the intrinsic apoptotic pathway. Recent preclinical studies have suggested that inhibition of BCL-2 may be a novel therapeutic strategy for patients with T-ALL. Herein, we report a case of clinical response to venetoclax in combination with a hypomethylating agent in a patient with relapsed T-ALL after allogeneic stem cell transplant and review the existing literature.
['Farhadfar|Nosha|N|', 'Li|Ying|Y|', 'May|William S|WS|', 'Adams|Carolyn Brooke|CB|']
D000328:Adult D064591:Allografts D000971:Antineoplastic Combined Chemotherapy Protocols D019086:Bridged Bicyclo Compounds, Heterocyclic D000077209:Decitabine D005260:Female D006801:Humans D054218:Precursor T-Cell Lymphoblastic Leukemia-Lymphoma D012008:Recurrence D033581:Stem Cell Transplantation D013449:Sulfonamides
Venetoclax Acute lymphoblastic leukemia BCL-2